CYAD News and Press, Celyad SA From 03/23/23

Starting in 2023, Celyad Oncology is now entirely focused on its new business strategy with one clear objective: help to overcome the current limitations of CAR-T approaches. It plans to do this via (i) strengthening of its research focus centered around NKG2D, B7-H6 and shRNA platforms; (ii) max...

MONT-SAINT-GUIBERT, Belgium, March 17, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today anno...

2023-03-15 05:33:18 ET Celyad Oncology ( NASDAQ: CYAD ) said it will recognize a non-cash impairment of its goodwill and intangible oncology assets; and that its board plans to submit for a vote its business plan, including a proposal to continue the company's activiti...

MONT-SAINT-GUIBERT, Belgium, March 15, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today anno...

MONT-SAINT-GUIBERT, Belgium, March 01, 2023 (GLOBE NEWSWIRE) -- The following is a statement by Celyad Oncology: Dear Shareholder, 2022 has been a crossroad year for Celyad Oncology (the “Company”), with important changes and turning points. Whilst our clinical programs...

MONT-SAINT-GUIBERT, Belgium, Feb. 28, 2023 (GLOBE NEWSWIRE) -- The following is a statement by Celyad Oncology: Dear Shareholder, 2022 has been a crossroad year for Celyad Oncology (the “Company”), with important changes and turning points. Whilst our clinical programs ...

MONT-SAINT-GUIBERT, Belgium, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today annou...

Biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen receptor T-cell therapies, Celyad Oncology ( NASDAQ: CYAD ) gives Q4 outlook , expects FY 2022 unaudited treasury position of €12.4M ($13.3M). The company is ...

Celyad Oncology has implemented a strategic shift from an organization focused on clinical development to one fully harnessing the true potential of its proprietary technology platforms and intellectual property The company is now prioritizing internal discovery endeavors to tackle the majo...

Palm Beach, FL – January 19, 2023 – FinancialNewsMedia.com News Commentary – Gamma Delta T Cell Therapy represents one of the most promising T Cell therapies in clinical development. The introduction of T cell-based immunotherapy has greatly revolutionized the par...